Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(CRWE, PSTI, FACE, VICL) Stock Market Report


FREE Daily Stock Alerts From


Pluristem Therapeutics, Inc. (Nasdaq:PSTI), a leading developer of placenta-based cell therapies, reported that it has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacental eXpanded (NYSEMKT:PLX) cells.

Fisher BioServices will provide cryogenic storage and distribution of Pluristem's PLX cells for its clinical trials and preclinical sites around the world.


Since the World Wide Web is so widely available, businesses can access millions of potential customers with just a few clicks of their mouse.

Crown Equity Holdings Inc., (OTCPK:CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWE’s division CRWE AD-Services (, is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

More about CRWE at


Physicians Formula Holdings, Inc. (Nasdaq:FACE) and Markwins International Corporation reported they have entered into a definitive merger agreement under which Markwins will acquire all of the outstanding shares of common stock of Physicians Formula for $4.90 per share in cash, or approximately $74.9 million.

The per share price represents a premium of approximately 33% to Physicians Formula's closing stock price on August 14, 2012 (the trading day prior to the announcement that Physicians Formula entered into a merger agreement with affiliates of Swander Pace Capital) and a premium of approximately 40% to Physicians Formula's one-month volume-weighted average price as of that same date.


Vical Incorporated (Nasdaq:VICL) will present at the MD Becker Partners' 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 4, at 1:15 p.m. ET, at the New York Academy of Medicine.

Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of its Allovectin(r) immunotherapy program, including mechanisms of action, summary clinical results, and current status and outlook in the ongoing Phase 3 registration trial in patients with metastatic melanoma.



Disclaimer: publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.